UY38070A - Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer - Google Patents
Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncerInfo
- Publication number
- UY38070A UY38070A UY38070A UY38070A UY38070A UY 38070 A UY38070 A UY 38070A UY 38070 A UY38070 A UY 38070A UY 38070 A UY38070 A UY 38070A UY 38070 A UY38070 A UY 38070A
- Authority
- UY
- Uruguay
- Prior art keywords
- quinazoline
- substitute
- cancer agents
- derivatives useful
- pyridopyrimidine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Abstract
Los compuestos de la fórmula general: procesos para la preparación de esos compuestos, composiciones que contienen esos compuestos y los usos de esos compuestos. procesos para la preparación de esos compuestos, composiciones que contienen esos compuestos y los usos de esos compuestos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862624829P | 2018-02-01 | 2018-02-01 | |
US201862685383P | 2018-06-15 | 2018-06-15 | |
US201962795062P | 2019-01-22 | 2019-01-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38070A true UY38070A (es) | 2019-08-30 |
Family
ID=65685851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY38070A UY38070A (es) | 2018-02-01 | 2019-01-31 | Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer |
Country Status (8)
Country | Link |
---|---|
US (1) | US10662204B2 (es) |
EP (1) | EP3746435B1 (es) |
JP (1) | JP7317028B2 (es) |
CA (1) | CA3089936C (es) |
ES (1) | ES2926373T3 (es) |
TW (1) | TW201942115A (es) |
UY (1) | UY38070A (es) |
WO (1) | WO2019150305A1 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7039489B2 (ja) | 2016-05-18 | 2022-03-22 | ミラティ セラピューティクス, インコーポレイテッド | Kras g12c阻害剤 |
KR20200100632A (ko) | 2017-11-15 | 2020-08-26 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
AR117194A1 (es) | 2018-11-09 | 2021-07-21 | Hoffmann La Roche | Compuestos de anillos fusionados |
US20220152026A1 (en) | 2019-02-12 | 2022-05-19 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
CN112390788A (zh) * | 2019-08-13 | 2021-02-23 | 苏州闻天医药科技有限公司 | 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途 |
CN114222743A (zh) * | 2019-08-16 | 2022-03-22 | 劲方医药科技(上海)有限公司 | 氧代六元环并嘧啶类化合物,其制法与医药上的用途 |
CN112390796B (zh) * | 2019-08-19 | 2023-06-27 | 贝达药业股份有限公司 | Kras g12c抑制剂及其在医药上的应用 |
CN112694475A (zh) * | 2019-10-23 | 2021-04-23 | 苏州泽璟生物制药股份有限公司 | 环烷基类和杂环烷基类抑制剂及其制备方法和应用 |
BR112022008534A2 (pt) | 2019-11-04 | 2022-08-09 | Revolution Medicines Inc | Compostos, composição farmacêutica, conjugado e métodos para tratar câncer e para tratar um distúrbio relacionado à proteína ras |
AU2020377925A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
JP2022553858A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ras阻害剤 |
CN112851663B (zh) * | 2019-11-12 | 2023-07-18 | 博瑞生物医药(苏州)股份有限公司 | 一种并杂环化合物及其用途 |
JP2023505100A (ja) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | 共有ras阻害剤及びその使用 |
CN114760994A (zh) * | 2019-12-04 | 2022-07-15 | 艾库斯生物科学有限公司 | HIF-2α的抑制剂 |
CN113024544A (zh) * | 2019-12-09 | 2021-06-25 | 武汉誉祥医药科技有限公司 | 一种含氰基并杂环化合物及其用途 |
US20230287021A1 (en) | 2020-01-28 | 2023-09-14 | Protego Biopharma, Inc. | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
TW202140450A (zh) * | 2020-02-24 | 2021-11-01 | 大陸商泰勵生物科技(上海)有限公司 | 用於癌症治療的kras抑制劑 |
WO2021188769A1 (en) | 2020-03-19 | 2021-09-23 | Arcus Biosciences, Inc. | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
EP4136088A1 (en) * | 2020-04-17 | 2023-02-22 | Dong-A ST Co., Ltd. | Pyridopyrimidinone derivatives and their use as aryl hydrocarbon receptor modulators |
MX2022016355A (es) | 2020-06-18 | 2023-04-03 | Revolution Medicines Inc | Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras. |
AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
WO2022060836A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
WO2022152313A1 (zh) * | 2021-01-18 | 2022-07-21 | 成都百裕制药股份有限公司 | 嘧啶衍生物及其在医药上的应用 |
CN113072480B (zh) * | 2021-04-13 | 2022-09-30 | 常州佳德医药科技有限公司 | 一种手性(-)-5-氮杂螺[2.4]庚烷-7-醇、制备方法及应用 |
KR20240004960A (ko) | 2021-05-05 | 2024-01-11 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
PE20240089A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer |
WO2022248885A2 (en) * | 2021-05-28 | 2022-12-01 | Redx Pharma Plc. | Compounds |
TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
TW202321206A (zh) | 2021-07-28 | 2023-06-01 | 美商普羅泰戈生物製藥股份有限公司 | 轉甲狀腺素蛋白穩定化合物 |
CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
WO2023056421A1 (en) * | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
CA3235146A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
WO2023154124A1 (en) * | 2022-02-09 | 2023-08-17 | Enliven Therapeutics, Inc. | Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2 |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023199180A1 (en) | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024006379A1 (en) * | 2022-06-30 | 2024-01-04 | Axonis Therapeutics, Inc. | Methods and compounds for inhibiting mkk7 enzymes |
WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
AR088694A1 (es) | 2011-11-17 | 2014-06-25 | Pfizer | Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos |
MX2016004360A (es) * | 2013-10-10 | 2016-08-19 | Araxes Pharma Llc | Inhibidores de kras g12c. |
KR20180005178A (ko) * | 2015-04-10 | 2018-01-15 | 아락세스 파마 엘엘씨 | 치환된 퀴나졸린 화합물 및 이의 사용방법 |
EP3325447A1 (en) * | 2015-07-22 | 2018-05-30 | Araxes Pharma LLC | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
EP3377481A1 (en) * | 2015-11-16 | 2018-09-26 | Araxes Pharma LLC | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
JP7039489B2 (ja) | 2016-05-18 | 2022-03-22 | ミラティ セラピューティクス, インコーポレイテッド | Kras g12c阻害剤 |
-
2019
- 2019-01-29 TW TW108103302A patent/TW201942115A/zh unknown
- 2019-01-31 CA CA3089936A patent/CA3089936C/en active Active
- 2019-01-31 EP EP19709113.5A patent/EP3746435B1/en active Active
- 2019-01-31 UY UY38070A patent/UY38070A/es unknown
- 2019-01-31 ES ES19709113T patent/ES2926373T3/es active Active
- 2019-01-31 JP JP2020542110A patent/JP7317028B2/ja active Active
- 2019-01-31 US US16/263,185 patent/US10662204B2/en active Active
- 2019-01-31 WO PCT/IB2019/050795 patent/WO2019150305A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3746435B1 (en) | 2022-08-03 |
CA3089936C (en) | 2023-02-28 |
ES2926373T3 (es) | 2022-10-25 |
EP3746435A1 (en) | 2020-12-09 |
JP7317028B2 (ja) | 2023-07-28 |
US20190233440A1 (en) | 2019-08-01 |
CA3089936A1 (en) | 2019-08-08 |
US10662204B2 (en) | 2020-05-26 |
WO2019150305A1 (en) | 2019-08-08 |
JP2021512131A (ja) | 2021-05-13 |
TW201942115A (zh) | 2019-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY38070A (es) | Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer | |
UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
NI201700095A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
NI201800128A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
CL2018000730A1 (es) | Compuestos heterocíclicos y usos de los mismos | |
UY37124A (es) | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
ECSP19089214A (es) | Inhibidores de quinasa y usos de los mismos | |
CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
CR20110610A (es) | Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades | |
CU20180027A7 (es) | DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN | |
UY32383A (es) | Dionas cíclicas herbicidamente activas, derivados, procesos para su preparación composiciones que las comprenden y usos de las mismas | |
NI201700129A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa. | |
CO2019012767A2 (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
ECSP18074962A (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
CO2020007044A2 (es) | Derivados de pirrol como inhibidores de acc | |
UY37016A (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
SV2018005657A (es) | "nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparacion y composiciones farmaceuticas que los contienen" | |
CL2018003121A1 (es) | Inhibidores del potenciador del homólogo zeste 2. | |
CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
UY36195A (es) | Amidas de benzoxazinona como reguladores del receptor mineralocorticoide | |
UY37191A (es) | Derivados de dibenzofurano para uso como inhibidores de bromodominio | |
DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
CO2018012020A2 (es) | Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3 |